COVID-19 Vaccines: Global Regulators Define Preclinical Data Requirements
Address Thorny Issue Of Studying Vaccine-Induced Disease Enhancement
Executive Summary
Regulators held a virtual meeting to agree on the type and extent of preclinical data needed to inform the clinical development of vaccines for COVID-19.
You may also be interested in...
New EMA System By Year End To Monitor COVID-19 Vaccine Safety
During a virtual workshop with global drug regulators, the European Medicines Agency discussed its plans to build a new EU system to track the safety of COVID-19 vaccines. Also, regulators agreed on exchanging information on observational studies and real-world data relating to the coronavirus pandemic.
Regulators Exchange Info On COVID-19 Vaccines, EU Urges Pooling Resources
Regulators are trying to keep sight of the bigger picture amidst disparate efforts to develop potential treatments and vaccines for the coronavirus outbreak. The World Health Organization and EU regulators are concerned that small individual studies may not be in the best interests of patients and are suggesting pooling resources.
EU Regulators Explain How To Ensure Transitioned Trials Align With CTR
Members of the EU’s Clinical Trials Coordination Group have developed harmonized requirements for updating trials that are transitioned to the Clinical Trials Information System based on a minimum set of documents.